Sara Jane MacLennan

Sara Jane MacLennan

Auto-generated profile, based on publicly available information

Sara Jane MacLennan

Academic Urology Unit, University of Aberdeen, Aberdeen, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in European Urology
Verified
Journal Article
Closed access
SMSteven MacLennan
Steven MacLennan
MIMari Imamura
Mari Imamura
MLMarie C. Lapitan
Marie C. Lapitan
Muhammad Imran OmarMuhammad Imran Omar
Muhammad Imran Omar
TLThomas B.L. Lam
Thomas B.L. Lam
JNJames N'Dow
James N'Dow

1 December 2012 in European Urology
Verified
Journal Article
Closed access
SMSteven MacLennan
Steven MacLennan
MIMari Imamura
Mari Imamura
MLMarie C. Lapitan
Marie C. Lapitan
Muhammad Imran OmarMuhammad Imran Omar
Muhammad Imran Omar
TLThomas B.L. Lam
Thomas B.L. Lam
JNJames N’dow
James N’dow

1 October 2013 in Maturitas
Verified
Journal Article
Open access
Amanda GriffithsAmanda Griffiths
Amanda Griffiths
SMSara Jane MacLennan
Sara Jane MacLennan
Juliet HassardJuliet Hassard
Juliet Hassard
This study explored women's experiences of working through menopausal transition in the UK. It aimed to identify the perceived effects of menopausal symptoms on working life, to outline the perceived effects of work on menopausal symptoms, and to provide recommendations for women, healthcare practitioners and employers. An electronic questionnaire was distributed to women aged 45-55 in professional, managerial and administrative (non-manual) occupations in 10 organisations. Items included: age, age and gender of line manager, educational level, job satisfaction; menopausal status; symptoms that were problematic for work; hot flushes; working conditions; work performance, disclosure to line managers; individual coping strategies; and, effective workplace adjustments and employer support. The final sample comprised 896 women. Menopausal transition caused difficulties for some women at work. The most problematic symptoms were: poor concentration, tiredness, poor memory, feeling low/depressed and lowered confidence. Hot flushes were particularly difficult. Some women felt work performance had been negatively affected. The majority of women were unwilling to disclose menopause-related health problems to line managers, most of whom were men or younger than them. Individual coping strategies were described. Four major areas for organisational-level support emerged: (i) greater awareness among managers about menopause as a possible occupational health issue, (ii) flexible working hours, (iii) access to information and sources of support at work, and (iv) attention to workplace temperature and ventilation. Employers and healthcare practitioners should be aware that menopausal transition causes difficulty for some women at work, and that much can be done to support them.

1 July 2015 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
CRCraig R Ramsay
Craig R Ramsay
TATemitope E Adewuyi
Temitope E Adewuyi
JGJoanne Gray
Joanne Gray
JHJenni Hislop
Jenni Hislop
MSMark Df Shirley
Mark Df Shirley
TLThomas B Lam
Thomas B Lam
Background: For people with localised prostate cancer, active treatments are effective but have significant side effects. Minimally invasive treatments that destroy (or ablate) either the entire gland or the part of the prostate with cancer may be as effective and cause less side effects at an acceptable cost. Such therapies include cryotherapy, high-intensity focused ultrasound (HIFU) and brachytherapy, among others.Objectives: This study aimed to determine the relative clinical effectiveness and cost-effectiveness of ablative therapies compared with radical prostatectomy (RP), external beam radiotherapy (EBRT) and active surveillance (AS) for primary treatment of localised prostate cancer, and compared with RP for salvage treatment of localised prostate cancer which has recurred after initial treatment with EBRT.Data sources: MEDLINE (1946 to March week 3, 2013), MEDLINE In-Process & Other Non-Indexed Citations (29 March 2013), EMBASE (1974 to week 13, 2013), Bioscience Information Service (BIOSIS) (1956 to 1 April 2013), Science Citation Index (1970 to 1 April 2013), Cochrane Central Register of Controlled Trials (CENTRAL) (issue 3, 2013), Cochrane Database of Systematic Reviews (CDSR) (issue 3, 2013), Database of Abstracts of Reviews of Effects (DARE) (inception to March 2013) and Health Technology Assessment (HTA) (inception to March 2013) databases were searched. Costs were obtained from NHS sources.Review methods: Evidence was drawn from randomised controlled trials (RCTs) and non-RCTs, and from case series for the ablative procedures only, in people with localised prostate cancer. For primary therapy, the ablative therapies were cryotherapy, HIFU, brachytherapy and other ablative therapies. The comparators were AS, RP and EBRT. For salvage therapy, the ablative therapies were cryotherapy and HIFU. The comparator was RP. Outcomes were cancer related, adverse effects (functional and procedural) and quality of life. Two reviewers extracted data and carried out quality assessment. Meta-analysis used a Bayesian indirect mixed-treatment comparison. Data were incorporated into an individual simulation Markov model to estimate cost-effectiveness.Results: The searches identified 121 studies for inclusion in the review of patients undergoing primary treatment and nine studies for the review of salvage treatment. Cryotherapy [3995 patients; 14 case series, 1 RCT and 4 non-randomised comparative studies (NRCSs)], HIFU (4000 patients; 20 case series, 1 NRCS) and brachytherapy (26,129 patients; 2 RCTs, 38 NRCSs) studies provided limited data for meta-analyses. All studies were considered at high risk of bias. There was no robust evidence that mortality (4-year survival 93% for cryotherapy, 99% for HIFU, 91% for EBRT) or other cancer-specific outcomes differed between treatments. For functional and quality-of-life outcomes, the paucity of data prevented any definitive conclusions from being made, although data on incontinence rates and erectile dysfunction for all ablative procedures were generally numerically lower than for non-ablative procedures. The safety profiles were comparable with existing treatments. Studies reporting the use of focal cryotherapy suggested that incontinence rates may be better than for whole-gland treatment. Data on AS, salvage treatment and other ablative therapies were too limited. The cost-effectiveness analysis confirmed the uncertainty from the clinical review and that there is no technology which appears superior, on the basis of current evidence, in terms of average cost-effectiveness. The probabilistic sensitivity analyses suggest that a number of ablative techniques are worthy of further research.Limitations: The main limitations were the quantity and quality of the data available on cancer-related outcomes and dysfunction.Conclusions: The findings indicate that there is insufficient evidence to form any clear recommendations on the use of ablative therapies in order to influence current clinical practice. Research efforts in the use of ablative therapies in the management of prostate cancer should now be concentrated on the performance of RCTs and the generation of standardised outcomes.Study registration: This study is registered as PROSPERO CRD42012002461.Funding: The National Institute for Health Research Health Technology Assessment programme.

1 November 2013 in European Urology
Verified
Journal Article
Closed access
HBHendrika J. Bekema
Hendrika J. Bekema
SMSteven MacLennan
Steven MacLennan
MIMari Imamura
Mari Imamura
TLThomas B.L. Lam
Thomas B.L. Lam
FSFiona Stewart
Fiona Stewart
JNJames N'DOw
James N'DOw

23 September 2014 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TLThomas B L Lam
Thomas B L Lam
Muhammad Imran OmarMuhammad Imran Omar
Muhammad Imran Omar
EFEuan Fisher
Euan Fisher
KGKatie Gillies
Katie Gillies
SMSara MacLennan
Sara MacLennan